$KLRA News

Kailera Therapeutics (KLRA) Reports Wider Losses And Names New CTO, Is The Low P B Justified?

Kailera Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kailera Therapeutics Q2 EPS $(1.09) Misses $(0.74) Estimate

Kailera Therapeutics Appoints Nur Nicholson as Chief Technology Officer

Kailera Therapeutics (KLRA) is One of the Best IPO Stocks with Huge Upside Potential

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

Kailera weight loss pill trial results: Nausea sinks stock

Update: Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial; Shares Fall

Why Is Kailera Therapeutics Stock Falling Tuesday?

Kailera Says Oral Small Molecule KAI-7535 Achieves Up to 11% Weight Loss in Phase 3 Trial

Kailera Therapeutics Announces Positive Topline Data from Two Hengrui Pharma Phase 3 Clinical Trials of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535/KAI-7535

Kailera Therapeutics Announces Topline Data From Two Additional Phase 3 Clinical Trials Of Oral Small Molecule GLP-1 Receptor Agonist HRS-7535 Conducted By Hengrui Pharma In China

Kailera Therapeutics (KLRA) Stock Looks Overvalued Despite Its 20% Slump

Hengrui Pharma and Kailera Therapeutics Present Ribupatide Clinical Data at ADA 2026

Kailera Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference

Kailera Reports First Quarter 2026 Financial Results and Provides Clinical Data Updates

Kailera Therapeutics Q1 EPS $(3.65) Misses $(0.68) Estimate as R&D Spend Jumps to $70.9M

Hengrui Pharma, Kailera Therapeutics To Present Two Abstracts At 86th Scientific Sessions Of The American Diabetes Association

Leerink Partners Initiates Coverage On Kailera Therapeutics with Outperform Rating, Announces Price Target of $36

Jefferies Initiates Coverage On Kailera Therapeutics with Buy Rating, Announces Price Target of $48